An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus ...

In a statement, J&J said that the trial – which looked at the combination of TAR-200 with J&J's experimental PD-1 inhibitor cetrelimab given systemically – was "a bold approach to disrupt the ...

The SunRISe-1 trial also assessed TAR-200 with cetrelimab and as monotherapy in different cohorts, focusing on safety and efficacy. The application is being submitted through the FDA’s Real-Time ...

Cetrelimab is under clinical development by Johnson & Johnson and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase III drugs for Muscle Invasive Bladder ...

SunRISe-1 is an ongoing randomized, phase 2b study evaluating efficacy and safety of TAR-200 + cetrelimab (Cohort 1), TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) in patients with BCG ...

Ninety patients will be randomized to daily erdafitinib monotherapy versus combination erdafitinib + cetrelimab. The co-primary study endpoints are pathologic complete response and downstaging.

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients with pretreated advanced urothelial carcinoma. Physician’s choice of ...